Monkeypox outbreak: Tecovirimat or Brincidofovir? Which drug is beneficial?
Live MintAt least one antiviral medicine shows promise against monkeypox and should be investigated further, scientists said as the outbreak widens. The scientists said more work is needed to reach any conclusions but their study found little evidence that another drug, brincidofovir, was beneficial. “Our paper gives a signal that if you had the choice between the two drugs, tecovirimat has shown more promise so far,” Hugh Adler, a researcher at the Liverpool University Hospitals NHS Foundation Trust and lead author, told reporters in a briefing, while urging caution. “We hope that by sharing this data other clinicians who are dealing with cases, particularly if they’re severe cases of monkeypox, might be able to access this drug as well, and that people will have the incentive to do a bigger study.” The cousin of the smallpox virus has spread across Europe and the U.S. in recent days, leading to 131 confirmed cases and another 106 suspected ones across 19 nations, according to the World Health Organization. Brincidofovir didn’t appear to have convincing clinical benefit in three other patients treated with the drug seven days after the initial onset of a rash, researchers said.